Bradley Orris, MD
Urology · Greenwood, INNPI 1760496756
Payments from drug & device makers
What this record shows
This record is dominated by other: $22,071 of the $29,410 with a category attached, or 75.0%. Central Indiana URS Consumables, LLC accounts for 75.0% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2024 at $19,053 and has fallen 59.0% since, to $7,808 in 2025.
Across 143 payments — averaging $205.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Central Indiana URS Consumables, LLC$22K
- Procept Biorobotics Corporation$3K
- Neotract Inc.$1K
- Bayer$369
- Dendreon Pharmaceuticals LLC$361
- AbbVie$273
- plus $2K from 33 others
Across 2 payments — averaging $7800.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Central Indiana URS Consumables, LLC$16K
What the payments were for
- Travel & lodging$3,45512%
- Food & beverage$3,88413%
- Other$22,07175%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Central Indiana URS Consumables, LLC | 4 | $22,071 |
| Procept Biorobotics Corporation | 12 | $2,851 |
| Neotract Inc. | 8 | $1,163 |
| Bayer | 9 | $369 |
| Dendreon Pharmaceuticals LLC | 10 | $361 |
| AbbVie(2 entities) | 16 | $273 |
| Pfizer | 11 | $230 |
| Medtronic(2 entities) | 6 | $201 |
| Boston Scientific | 3 | $188 |
| Johnson & Johnson | 8 | $182 |
| Axonics, Inc. | 3 | $177 |
| Sumitomo Pharma America, Inc. | 8 | $174 |
| Calyxo, Inc. | 1 | $138 |
| Bioprotect Medical, Inc. | 2 | $105 |
| Urogen Pharma, Inc. | 4 | $92 |
| Progenics Pharmaceuticals, Inc. | 4 | $91 |
| Novartis | 3 | $84 |
| Coloplast | 4 | $77 |
| Sanofi | 3 | $76 |
| Laborie Medical Technologies Corp. | 2 | $71 |
| Healthtronics Stone Solutions, LLC | 1 | $41 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Teleflex LLC | 2 | $35 |
| Astellas Pharma US Inc | 2 | $31 |
| Myovant Sciences Inc. | 1 | $28 |
| Conmed Corporation | 1 | $27 |
| Vertex | 1 | $26 |
| Integra Lifesciences Corporation | 1 | $24 |
| Merck | 1 | $24 |
| Urovant Sciences Inc | 1 | $23 |
| AstraZeneca | 1 | $22 |
| Organon | 1 | $17 |
| Cook Medical LLC | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Olympus America Inc. | 1 | $15 |
| Immunitybio, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Clinigen, Inc. | 1 | $13 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dornier MedTech$88,286
- CVAC Aspiration System$22,210
- AQUABEAM SYSTEM$2,611
- UroLift$950
- AquaBeam Robotic System$149
- Nubeqa$147
- Xofigo$147
- GENERAL BPH$144
- PROVENGE$139
- INTERSTIM$121
- Axonics$115
How this compares
$29,410 in reported general payments places this provider in the 85th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 180 | $135,490 |
| GemtesaVibegron | 115 | $97,946 |
| Mirabegron ErMirabegron | 23 | $16,739 |
| Silodosin | 124 | $12,786 |
| Tamsulosin Hcl | 608 | $8,644 |
| Finasteride | 416 | $5,122 |
| Trospium Chloride | 70 | $4,092 |
| Solifenacin Succinate | 80 | $3,886 |
| Trospium Chloride ErTrospium Chloride | 20 | $3,260 |
| Methenamine Hippurate | 21 | $2,307 |
| Cephalexin | 292 | $2,182 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 74 | $1,566 |
| Dutasteride | 32 | $1,193 |
| NitrofurantoinNitrofurantoin Macrocrystal | 38 | $1,187 |
| Estradiol | 17 | $816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $31 | $135,490180 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $174 | $97,946115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 272 urology providers in Indiana.
Other urology in Greenwood
- Eugene ConeGreenwood$114K
- Brian OrrGreenwood$50K
- David GilleyGreenwood$31K
- James RaybournGreenwood$27K
- Weston KitleyGreenwood$24K
- Charles SchwabGreenwood$23K
- Alexander TatemCarmel$418K
- Chad ReichardCarmel$400K
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.